tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.58838/2075-1230-2023-101-5-69-76tiblj-1771Research ArticleОБЗОРREVIEWПереносимость детьми химиотерапии туберкулезаTolerability of Tuberculosis Chemotherapy in ChildrenЛозовскаяМ. Э.LozovskayaM. E.

Лозовская Марина Эдуардовна, Доктор медицинских наук, профессор, заведующая кафедрой фтизиатрии

Тел.: +7 (812) 321-33-36

194100, г. Санкт-Петербург, ул. Литовская, д. 2

Marina E. Lozovskaya, Doctor of Medical Sciences, Professor, Head of Phthisiology Department

Phone: +7 (812) 321-33-36

2, Litovskaya St., St. Petersburg, 194100

lozovskaja-marina@rambler.ruМотовИ. Ю.MotovI. Yu.

Мотов Игорь Юрьевич, Ассистент кафедры фтизиатрии

Тел.: +7 (812) 321-33-36

194100, г. Санкт-Петербург, ул. Литовская, д. 2

Igor Yu. Motov, Assistant of Phthisiology Department

Phone: +7 (812) 321-33-36

2, Litovskaya St., St. Petersburg, 194100

jesuigor123@mail.ruНовикГ. А.NovikG. A.

Новик Геннадий Айзикович, Доктор медицинских наук, профессор, заведующий кафедрой детских болезней им. профессора И. М. Воронцова факультета послевузовского и дополнительного профессионального образования

Тел.: +7 (812) 295-14-04

194100, г. Санкт-Петербург, ул. Литовская, д. 2

Gennady A. Novik, Doctor of Medical Sciences, Professor, Head of Pediatric Diseases Department Named after Professor I.M. Vorontsov, Faculty of Post-Graduate and Additional Professional Education

Phone: +7 (812) 295-14-04

2, Litovskaya St., St. Petersburg, 194100

ga_novik@mail.ruФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» МЗ РФРоссияSt. Petersburg State Pediatric Medical University, Russian Ministry of HealthRussian Federation20232412202310156976Copyright © Лозовская М.Э., Мотов И.Ю., Новик Г.А., 20232023Лозовская М.Э., Мотов И.Ю., Новик Г.А.Lozovskaya M.E., Motov I.Y., Novik G.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1771

В обзоре приводятся данные из 61 источника литературы. Актуальность темы определяется тем, что клинические испытания препаратов и схем химиотерапии обычно проводятся с участием взрослых, лишь небольшое число проведено на детском контингенте. Назначение противотуберкулезных препаратов у детей в клинической практике часто производится не по инструкции (off-label). Частота нежелательных реакций на препараты у детей колеблется в широких пределах в зависимости от подходов к их регистрации. Наиболее тяжелые и частые нежелательные явления связаны с поражением печени. В последние годы c участием педиатрических больных лекарственно-устойчивым туберкулезом прошли испытания фторхинолонов, бедаквилина, деламанида, показавшие их удовлетворительную переносимость и безопасность.

The article presents the review of 61 publications. The topic is highly relevant due to the fact that clinical trials of drugs and chemotherapy regimens usually enroll adults, while children participate only in a small number of them. Often in clinical practice, anti-tuberculosis drugs are prescribed to children off-label. The frequency of adverse reactions in children varies widely depending on approaches to their reporting. The most severe and frequent adverse events are associated with liver injury. In recent years, clinical trials of fluoroquinolones, bedaquiline, and delamanid were run in pediatric patients with drug resistant tuberculosis demonstrating satisfactory tolerability and safety of these drugs.

детитуберкулезмножественная лекарственная устойчивостьхимиотерапияпротивотуберкулезные препаратынежелательные реакцииchildrentuberculosismultiple drug resistancechemotherapyanti-tuberculosis drugsadverse reactionsReferencesАксенова В. А., Клевно Н. И., Казаков А. В., Кудлай Д. А., Пахлавонова А. Д., Сокольская Е. А., Наконечная С. Л. Эффективность и безопасность схемы химиотерапии с включением бедаквилина у детей с лекарственно-устойчивым туберкулезом // Медицинский совет. – 2021. – № 16. – С. 138–146.Aksenova V.A., Klevno N.I., Kazakov A.V., Kudlay D.A., Pakhlavonova A.D., Sokolskaya E.A., Nakonechnaya S.L. Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis Meditsinsky Soviet, 2021, no. 16, pp. 138-146. (In Russ.)Ароян А. Р., Леонтьева Е. С., Мордык А. В. Изменение подходов к химиотерапии у детей раннего возраста в течение 30-летнего периода. // Туберкулёз и болезни лёгких. – 2018. – Т. 96, № 10. – С. 20–22.Aroyan A.R., Leontyeva E.S., Mordyk A.V. Changes to approaches to chemotherapy in the children of tender age over 30-year period. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 10, pp. 20-22. (In Russ.)Баронова О. Д., Аксенова В. А., Лугинова Е. Ф. Долженко Е. Н. Использование рифапентина для превентивной химиотерапии детей из групп риска развития туберкулеза // Туберкулез и болезни легких. – 2022. – Т. 100, № 8. – С. 31–36.Baronova O.D., Aksenova V.A., Luginova E.F. Dolzhenko E.N. The use of rifapentine for preventive chemotherapy in children from risk groups of developing tuberculosis. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 8, pp. 31-36. (In Russ.)Борзакова С. Н., Рейзис А. Р. Принципы диагностики и терапии лекарственно-индуцированных поражений печени у детей, больных туберкулезом. // Российский вестник перинатологии и педиатрии. – 2018. – Т. 63, № 3. – С. 91–97.Borzakova S.N., Reyzis A.R. Principles of diagnosis and therapy of drug-induced liver injury in children with tuberculosis. Rossiyskiy Vestnik Perinatologii i Pediatrii, 2018, vol. 63, no. 3, pp. 91-97. (In Russ.)Брюхачева Е. О., Холодов А. А., Иванов В. И., Казуль Г. А., Пьянзова Т. В. Факторы риска диспепcического синдрома при проведении противотуберкулезной химиотерапии у детей // Туберкулез и болезни легких. – 2022. – Т. 100, № 9. – С. 6–10.Bryukhacheva E.O., Kholodov A.A., Ivanov V.I., Kazul G.A., Pyanzova T.V. Risk factors of dyspepsia development during anti-tuberculosis chemotherapy in children. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 9, pp. 6-10. (In Russ.)Васильева (Платова) Е. Б. Туберкулез органов дыхания у детей и подростков при поражениях печени вирусной и токсической этиологии. Авт. к.м.н., Москва, 1990. – 19 с.Vasilyeva (Platova) E.B. Tuberkulyoz organov dykhaniya u detey i podrostkov pri porazheniyakh pecheni virusnoy i toksicheskoy etiologii. Avtoref. diss. kand. med. nauk. [Respiratory tuberculosis in children and adolescents in viral lesions of liver and of toxic etiology. Synopsis of Cand. Diss.]. Moscow, 1990, 19 p.Губкина М. Ф., Хохлова Ю. Ю., Петракова И. Ю., Юхименко Н. В. Переносимость дифференцированных режимов химиотерапии у детейGubkina M.F., Khokhlova Yu.Yu., Petrakova I.Yu., Yukhimenko N.V. Tolerability of individual chemotherapy regimens in children suffering from respiratory tuberculosis and exposed to multiple and extensive drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 3, pp. 29-33. (In Russ.)с туберкулезом органов дыхания из очагов туберкулеза с множественной и широкой лекарственной устойчивостью // Туберкулёз и болезни лёгких. – 2021. – Т. 99, № 3. – С. 29–33.Gulyaeva N.A., Ivanova O.N., Luginova E.F., Guryeva O.I., Zolotareva N.A., Andreeva S.K. A clinical case of hemotoxic adverse reaction during anti-tuberculosis chemotherapy. Sovremennye Problemy Nauki i Obrazovaniya, 2018, no. 6, pp. 27. (In Russ.)Гуляева Н. А., Иванова О. Н., Лугинова Е. Ф., Гурьева О. И., Золотарева Н. А., Андреева С. К. Случай гемотоксической побочной реакции на фоне противотуберкулезной химиотерапии // Современные проблемы науки и образования. – 2018. – № 6. – С. 27.Danilova T.I., Barmina N.A., Borisova E.S., Maksimova L.A., Korneev Yu.V.. Experience of using bedaquiline in a young child with drug resistant tuberculosis and concurrent primary immunodeficiency. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 8, pp. 47-53. (In Russ.)Данилова Т. И., Бармина Н. А., Борисова Е. С., Максимова Л. А., Корнеев Ю. В. Опыт применения препарата бедаквилин у ребенка раннего возраста с лекарственно-устойчивым туберкулезом на фоне первичного иммунодефицита // Туберкулёз и болезни лёгких. – 2021. – Т. 99, № 8. – С. 47–53.Drobot N.N. Treatment of respiratory tuberculosis in children and adolescents: hepatotoxic reactions. Mezhdunarodny Journal Prikladnykh i Fundamentalnykh Issledovaniy, 2011, no. 8, pp. 63-64. (In Russ.)Дробот Н. Н. Лечение туберкулеза органов дыхания у детей и подростков: гепатотоксические реакции. // Международный журнал прикладных и фундаментальных исследований. – 2011. – № 8. – С. 63–64.Dubrovskaya N.A. Kliniko-immunologicheskiye proyavleniya pobochnogo deystviya rifampitsina pri lechenii tuberkuleza legkikh. Avtoref. diss. kand. med. nauk. [Clinical and immunological manifestations of adverse reactions to rifampicin in the treatment of pulmonary tuberculosis. Synopsis of Cand. Diss.]. Moscow, 1984, 21 p.Дубровская Н. А. Клинико-иммунологические проявления побочного действия рифампицина при лечении туберкулеза легких. Авт. к.м.н., Москва, 1984. – 21 с.Zubova E.D., Takhtokhodzhaeva G.R., Senchikhina O.Yu., Kiselevich O.K., Yusubova A.N., Vlasova E.E. Adverse reactions in children and adolescents when treated with 2 and 3 line drugs within anti-tuberculosis chemotherapy regimens. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2021, no. 1, pp. 45-53. (In Russ.)Зубова Е. Д., Тахтоходжаева Г. Р., Сенчихина О. Ю., Киселевич О. К., Юсубова А. Н., Власова Е. Е. Нежелательные побочные реакции у детей и подростков при применении в схемах химиотерапии туберкулеза препаратов второго и третьего ряда // Туберкулез и социально значимые заболевания. – 2021. – № 1 – С. 45–53.Ivanova D.A., Borisov S.E., Ryzhov A.M., Ivanushkina T.N. Frequency and profile of adverse reactions during treatment of new tuberculosis cases. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2016, no. 1, pp. 73-75. (In Russ.)Иванова Д. А., Борисов С. Е., Рыжов А. М., Иванушкина Т. Н. Частота и характер нежелательных побочных реакций при лечении впервые выявленных больных туберкулезом // Туберкулез и социально значимые заболевания. – 2016. – № 1. – С. 73–75.Klimov G.V., Ershova N.G., Bogdanova E.V. Adverse reactions during treatment of children ill with tuberculosis. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2018, no. 4, pp. 42-47. (In Russ.)Климов Г. В., Ершова Н. Г., Богданова Е. В. Нежелательные побочные реакции при лечении детей, больных туберкулезом // Туберкулез и социально-значимые заболевания. – 2018. – № 4. – С. 42–47.Klinicheskie rekomendatsii Tuberkulez u detey. [Clinical guidelines on tuberculosis in children]. 2022, Available: https://cr.minzdrav.gov.ru/recomend/507_2 Accessed July 28, 2023.Клинические рекомендации «Туберкулез у детей», 2022. URL: https://cr.minzdrav.gov.ru/recomend/507_2 [Дата обращения 28 июля 2023]Kolbin A.S. Klinicheskaya farmakologiya dlya pediatrov: uchebnoye posobiye. [Clinical pharmacology for pediatricians: a handbook]. Moscow, GEOTAR-Media Publ., 2022, 288 p.Колбин, А. С. Клиническая фармакология для педиатров: учебное пособие / А. С. Колбин. – Москва: ГЭОТАР-Медиа, 2022 – 288 с.Lozovskaya M.E., Kurova A.S., Vasilyeva E.B., Klochkova L.V. Specific features of the clinical course and chemotherapy of tuberculosis in children exposed to tuberculosis with different drug resistance patterns. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 9, pp. 22-27. (In Russ.)Лозовская М. Э., Курова А. С., Васильева Е. Б., Клочкова Л. В. Особенности клинического течения и химиотерапии туберкулеза у детей из очагов с различным спектром лекарственной чувствительности микобактерий // Туберкулёз и болезни лёгких. – 2019. – Т. 97, № 9. – С. 22–27.Panova L.V. Gepatotoksicheskie reaktsii na khimioterapiyu i ikh korrektsii u podrostkov bolnyikh tuberkulyozom. Avtoref. diss. kand. med. nauk. [Hepatotoxic reactions to chemotherapy and their management in adolescents suffering from tuberculosis. Synopsis of Cand. Diss.]. Moscow, 2001, 17 p.Панова Л. В. Гепатотоксические реакции на химиотерапию и их коррекция у подростков больных туберкулезом: Авт. дис. к. м. н. – Москва, 2001. – 17 с.Panova L.V., Ovsyankina E.S., Krushinskaya E.A., Khiteva A.Yu., Piskunova O.A.. Efficacy and safety of short-course chemotherapy regimens in older children and adolescents with multiple and extensive drug resistant respiratory tuberculosis. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 10, pp. 35-39. (In Russ.)Панова Л. В., Овсянкина Е. С., Крушинская Е. А., Хитева А. Ю., Пискунова О. А. Эффективность и безопасность укороченных режимов химиотерапии у детей старшего возраста и подростков, больных туберкулезом органов дыхания с множественной и широкой лекарственной устойчивостью возбудителя // Туберкулёз и болезни лёгких. – 2021. – Т. 99, № 10. – С. 35–39.Romanova M.A., Mordyk A.V., Merko E.A., Leontyeva E.S. Study of association of concomitant diseases with chemotherapy tolerability in children with active tuberculosis: results of a retrospective cohort research. Pediatricheskaya Pharmocologiya, 2016, vol. 13, no. 2, pp. 95-100. (In Russ.)Романова М. А., Мордык А. В., Мерко Е. А., Леонтьева Е. С. Изучение связи сопутствующих заболеваний с переносимостью химиотерапии у детей с активным туберкулезом: результаты ретроспективного когортного исследования. // Педиатрическая фармакология. – 2016. – Т. 13,Sapozhnikova P.A., Nikishova E.I., Perkhin D.V., Maryandyshev A.O. Diagnostics and treatment of multiple resistant tuberculosis in children and adolescents in Arkhangelsk Region. Tuberculosis and Lung Diseases, 2012, vol. 89, no. 8, pp. 44-49. (In Russ.)№ 2. – С. 95–100.Tashpulatova F.K., Abdusalomova M.I., Lozovskaya M.E. The tolerability of chemotherapy by children ill with tuberculosis. Evraziysky Vestnik Pediatrii, 2020, no. 2, pp. 35-38. (In Russ.)Сапожникова П. А., Никишова Е. И., Перхин Д. В., Марьяндышев А. О. Диагностика и лечение туберкулеза с множественной лекарственной устойчивостью возбудителя у детей и подростков в Архангельской области // Туберкулёз и болезни лёгких. – 2012. – Т. 89, № 8. – С. 44–49.Multidrug-resistant tuberculosis in children and adolescents in the WHO European Region: expert opinion. WHO, 2020. https://apps.who.int/iris/bitstream/handle/10665/331888/9789289054966-rus.pdfТашпулатова Ф. К., Абдусаломова М. И., Лозовская М. Э. Переносимость химиотерапии у больных детей туберкулезом. // Евразийский вестник педиатрии. – 2020. – № 2. – С. 35–38.Khomenko A.G. Tuberkulez. Rukovodstvo dlya vrachey. [Tuberculosis. Doctors' Manual]. Moscow, Meditsina Publ., 1996, 496 p.Туберкулез с множественной лекарственной устойчивостью возбудителя у детей и подростков в Европейском регионе ВОЗ. Экспертное мнение. ВОЗ 2020. https://apps.who.int/iris/bitstream/handle/10665/331888/978928Khokhlova Yu.Yu. Khimioterapiya tuberkuleza organov dykhaniyau detey iz ochagov s mnozhestvennoy i shirokoy lekarstvennoy ustoychivostyu vozbuditelya. Avtoref. diss. kand. med. nauk. [Chemotherapy for respiratory tuberculosis in children exposed to the infection with multiple and extensive drug resistance. Synopsis of Cand. Diss.]. Moscow, 2020, 18 p.-rus.pdfAbdusalomova M., Denisiuk O., Davtyan H., Gadoev J., Abdusamatova B., Parpieva N., Sodikov A. Adverse Drug Reactions among Children with Tuberculosis in Tashkent, Uzbekistan, 2019. International Journal of Environmental Research and Public Health, 2021, vol. 18, no. 14, pp. 7574.Хоменко А. Г. Туберкулез. Руководство для врачей – М.: Медицина, 1996. – 496 с.Аchar J., Hewinson C., Cavalheiro A.P., Skrahina A., Cajazeiro J., Nargiza P. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Emerg. Infect. Dis., 2017, vol. 23, no. 10, pp. 1711-1713.Хохлова Ю.Ю. Химиотерапия туберкулеза органов дыхания у детей из очагов с множественной и широкой лекарственной устойчивостью возбудителя: Авт. дис. к. м. н. – Москва, 2020. – 18 с.Alam S., Lal B.B., Khanna R., Sood V., Rawat D. Acute Liver Failure in Infants and Yung Children in a Specialized Pediatric Liver Centre in India. The Indian Journal of Pediatrics, 2015, no. 82, pp. 879-883.Abdusalomova M., Denisiuk O., Davtyan H., Gadoev J., Abdusamatova B., Parpieva, N., Sodikov A. Adverse Drug Reactions among Children with Tuberculosis in Tashkent, Uzbekistan, 2019 //International Journal of Environmental Research and Public Health. – 2021. – Vol. 18, № 14. – P. 7574.Alsuhaibani, M., Felimban, G., Shoukri, M., Alosaimi, A., Almohaizeie, A., Al Hajjar, S.Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children. International Journal of Pediatrics and Adolescent Medicine, 2019, vol. 6, no. 2, pp. 47-50.Аchar J., Hewinson C., Cavalheiro A. P., Skrahina A., Cajazeiro J., Nargiza P. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis // Emerg. Infect. Dis. – 2017. –Vol. 23, № 10. – P. 1711–1713.Bradley J.S., Kauffman R.E., Balis D.A. et al. Assessment of musculoskeletal toxity 5 years after therapy with levofloxacin. Pediatrics, 2014, vol. 134, no. 1, pp. 146-153.Alam S., Lal B. B., Khanna R., Sood V., Rawat D. Acute Liver Failure in Infants and Yung Children in a Specialized Pediatric Liver Centre in India. // The Indian Journal of Pediatrics. – 2015. – № 82. – P. 879–883.Cui-ping L.I., Xiang L.I., Shao-mei H.U.A.N.G., Xiao-xia W.A.N.G., Xiao-qi L.I., Hai-xia H.U., Yi-min F.A.N.G. Efficacy and safety of linezolid in the treatment of children with severe tuberculous meningitis. China Tropical Medicine, 2021, vol. 21, no. 11, pp. 157-165.Alsuhaibani, M., Felimban, G., Shoukri, M., Alosaimi, A., Almohaizeie, A., Al Hajjar, S. Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children //International Journal of Pediatrics and Adolescent Medicine. – 2019. – Vol. 6, № 2. – P. 47–50.D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, Esposito S, Migliori GB. Delamanid and bedaquiline to treat multidrug-resistant and extensively drugresistant tuberculosis in children: a systematic review. J. Thorac. Dis., 2017, vol. 9, no. 7, pp. 2093-2101.Bradley J. S., Kauffman R. E., Balis D. A., et al. Assessment of musculoskeletal toxity 5 years after therapy with levofloxacin // Pediatrics. – 2014. – Vol. 134, № 1. – P. 146–153.Devarbhavi H., Karanth D., KS P, CK A, Patil M. Drug‐Induced liver injury with hypersensitivity features has a better outcome: a single‐center experience of 39 children and adolescents. Hepatology, 2011, vol. 54, no. 4, pp. 1344-1350.Cui-ping L. I., Xiang L. I., Shao-mei H. U. A. N. G., Xiao-xia W. A. N. G., Xiao-qi L. I., Hai-xia H. U., Yi-min F. A. N. G. Efficacy and safety of linezolid in the treatment of children with severe tuberculous meningitis // China Tropical Medicine. – 2021. – Vol. 21, № 11. – P. 157–165.Dixit A., Rarandikar M.V., Jones S., Nakamura M.M. Safety and tolerability of moxifloxacin in children. J. Pediatric. Infect. Dis. Soc., 2018, vol. 7, Sept. pp. e-92-e101.D'Ambrosio L., Centis R., Tiberi S., Tadolini M., Dalcolmo M., Rendon A., Esposito S., Migliori G. B. Delamanid and bedaquiline to treat multidrug-resistant and extensively drugresistant tuberculosis in children: a systematic review // J. Thorac Dis. – 2017. – Vol. 9, № 7. – P. 2093–2101.Ettehad D, Schaaf H.S., Seddon J.A., Cooke G.S., Ford N. Treatment outcomes for children with multidrug resistant tuberculosis: a systemic review and meta-analysis. Lancet Infect Dis., 2012, 24, no. 12, pp. 449-456.Devarbhavi H., Karanth D., KS P, CK A, Patil M. Drug‐Induced liver injury with hypersensitivity features has a better outcome: a single‐center experience of 39 children and adolescents. // Hepatology. – 2011. – Vol. 54, № 4. – С. 1344–1350.Garcia-Prats Anthony J., Heather R. Draper, Heather Finlayson, Jana Winckler, André Burger, Barend Fourie, Stephanie Thee, Anneke C. Hesseling, H. Simon Schaaf Author Notes. Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug- resistant Tuberculosis. Clinical Infection Diseases, 2018, vol. 67, no. 11, pp. 1777–1780.Dixit A., Rarandikar M. V., Jones S., Nakamura M. M. Safety and tolerability of moxifloxacin in children // J. Pediatric. Infect. Dis. Soc. – 2018. Vol. 7 (Sept). – P. e-92-e101.Garcia-Prats A.J., Schaaf H.S., Draper H.R., Garcia-Cremades M., Winckler J., Wiesner L., Savic R.M. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies. PLos Medicine, 2019, vol. 16, no. 4, pp. e1002789.Ettehad D., Schaaf H. S., Seddon J. A., Cooke G. S., Ford N. Treatment outcomes for children with multidrug resistant tuberculosis: a systemic review and meta-analysis// Lancet Infect. Dis. – 2012. – № 12 – Р. 449–456.Global tuberculosis report 2022. Geneva, World Health Organization, 2022. Available: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 Accessed August 23, 2023Garcia-Prats Anthony J., Heather R. Draper, Heather Finlayson, Jana Winckler, André Burger, Barend Fourie, Stephanie Thee, Anneke C. Hesseling, H. Simon Schaaf Author Notes. Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug- resistant Tuberculosis // Clinical Infectious Diseases. – 2018. – Vol. 67, № 11. – P. 1777–1780.Jackson M.A., Schutze G.E. Committee on Infectiuos Diseases. The use of systemic and topical fluoroquinolones. Pediatrics, 2016, vol. 138, no. 5, pp. 1-14.Garcia-Prats A. J., Schaaf H. S., Draper H. R., Garcia-Cremades M., Winckler J., Wiesner L., Savic R. M. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies //PLoS medicine. – 2019. – Vol. 16, № 4. – Р. e1002789.Jantarabenjakul W., Suntarattiwong P., Wacharachaisurapol N., Ayudhya, P.S.N., Phaisal W., Tawan M., Puthanakit T. Pharmacokinetics and Safety of WHO-Recommended Dosage and Higher Dosage of Levofloxacin for Tuberculosis Treatment in Children: a Pilot Study. International Journal of Infectious Diseases, 2022, vol. 122, pp. 603-608.Global tuberculosis report 2022. Geneva: World Health Organization; 2022. URL: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/Hughes J.A., Solans B.P., Draper H.R., Schaaf H.S., Winckler J.L., van der Laan L., Garcia-Prats A.J. Pharmacokinetics and safety of bedaquiline in human immunodeficiency virus (HIV)-positive and negative older children and adolescents with rifampicin-resistant tuberculosis. Clinical Infection Diseases, 2022, vol. 75, no. 10, pp. 1772-1780.global-tuberculosis-report-2022 [ Availablie at 23 Aug 2023]Keating A.V., Soto J., Forbes C., Zhao M., Craig D.Q. Multi-methodological quantitative taste assessment of anti-tuberculosis drugs to support the development of palatable paediatric dosage forms. Pharmaceutics, 2020, vol. 12, no. 4, pp. 369.Jackson M. A., Schutze G. E. Cjmmittee on Infectiuos Diseases. The use of systemic and topical fluoroquinolones // Pediatrics. – 2016. – Vol. 138, № 5 – P. 1–14.Laghari M., Talpur B.A., Sulaiman S.A.S., Khan A.H., Bhatti Z. Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis. International Journal of Mycobacteriology, 2020, vol. 9, no. 3, pp. 281.Jantarabenjakul, W., Suntarattiwong, P., Wacharachaisurapol, N., Ayudhya, P. S. N., Phaisal, W., Tawan, M., Puthanakit, T. Pharmacokinetics and Safety of WHO-Recommended Dosage and Higher Dosage of Levofloxacin for Tuberculosis Treatment in Children: a Pilot Study //International Journal of Infectious Diseases. – 2022. – Vol. 122. – P. 603–608.Li Y, Zhu Y., Zhong Q., Zhang X., Shu M., Wan C. Serious adverse reactions from anti-tuberculosis drugs among 599 children hospitalized for tuberculosis. The Pediatric Infectious Disease Journal, 2017, no. 36, pp. 720-725.Hughes, J. A., Solans, B. P., Draper, H. R., Schaaf, H. S., Winckler, J. L., van der Laan, L., Garcia-Prats, A. J. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents with Rifampicin-Resistant Tuberculosis // Clinical Infectious Diseases. – 2022. – Vol. 75, № 10. – P. 1772–1780.Morris S.K., Giroux R.J., Consunji-Araneta R., Stewart K., Baikie M., Kakkar F., Kitai I. Epidemiology, clinical features and outcomes of incident tuberculosis in children in Canada in 2013–2016: Results of a national surveillance study. Archives of Disease in Childhood, 2021, vol. 106, no. 12, pp. 1165-1170.Keating A. V., Soto J., Forbes C., Zhao M., Craig D. Q. Multi-methodological quantitative taste assessment of anti-tuberculosis drugs to support the development of palatable paediatric dosage forms //Pharmaceutics. – 2020. – Т. 12, № 4. – С. 369.Nansumba M., Kumbakumba E., Orikiriza P., Bastard M., Mwanga J.A., Boum Y., Bonnet M. Treatment outcomes and tolerability of the revised WHO anti-tuberculosis drug dosages for children. The International Journal Tuberculosis and Lung Diseases, 2018, vol. 22, no. 2, pp. 151-157.Laghari M., Talpur B. A., Sulaiman S. A. S., Khan A. H., Bhatti Z. Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis //International journal of mycobacteriology. – 2020. – Vol. 9, № 3. – P. 281.Naranjo C.A, Busto U., Sellers E.M. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol Ther., 1981, no. 30, pp 239-245.Li Y., Zhu Y., Zhong Q., Zhang X., Shu M., Wan C. Serious adverse reactions from anti-tuberculosis drugs among 599 children hospitalized for tuberculosis. // The pediatric infectious disease journal. – 2017. – № 36. – P. 720–725.Puspaningrum N.R., Aryani T., Setyoningrum R.A., Husna N.A. Anti-tuberculosis medicine in children with miliary tuberculosis or tuberculosis meningitis. Journal of Computational and Theoretical Nanoscience, 2021, vol. 18, no. 1-2, pp. 82-89.Morris S. K., Giroux R. J., Consunji-Araneta R., Stewart K., Baikie M., Kakkar F., Kitai I. Epidemiology, clinical features and outcomes of incident tuberculosis in children in Canada in 2013–2016: Results of a national surveillance study //Archives of Disease in Childhood. – 2021. – Vol. 106, № 12. – P. 1165–1170.Rose P.C., Hallbauer U.M., Seddon J.A., Hesseling A.C., Schaaf H.S. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. The International Journal Tuberculosis and Lung Diseases, 2012, vol. 16, no. 12, pp. 1588-1593.Nansumba M., Kumbakumba E., Orikiriza P., Bastard M., Mwanga J. A., Boum Y., Bonnet M. Treatment outcomes and tolerability of the revised WHO anti-tuberculosis drug dosages for children //The International Journal of Tuberculosis and Lung Disease. – 2018. – Vol. 22, № 2. – P. 151–157.Sasaki T., Svensson E.M., Wang X., Wang Y., Hafkin J., Karlsson M.O., Mallikaarjun S. Population pharmacokinetic and concentration-qtc analysis of delamanid in pediatric participants with multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 2022, vol. 66, no. 2, pp. e01608-21.Naranjo C.A, Busto U., Sellers E.M. A method for estimating the probability of adverse drug reactions // Clin. Pharmacol, Ther. – 1981. – № 30. – P. 239–245.Schaaf H.S. Diagnosis and management of multidrug-resistant tuberculosis in children: a practical approach. The Indian Journal of Pediatrics, 2019, vol. 86, no. 8, pp. 717–724.Puspaningrum N. R., Aryani T., Setyoningrum R. A., Husna N. A. Anti Tuberculosis Medicine in Children with Miliary Tuberculosis or Tuberculosis Meningitis // Journal of Computational and Theoretical Nanoscience. – 2021. – Vol. 18, № 1–2. – P. 82–89.Schaaf H.S., Thee S., van der Laan L., Hesseling A.C., Garcia-Prats A.J. Adverse effects of oral second-line antituberculosis drugs in children. Expert Opinion on Drug Safety, 2016, vol. 15, no. 10, pp. 1369-1381.Rose P. C., Hallbauer U. M., Seddon J. A., Hesseling A. C., Schaaf H. S. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children // The International journal of tuberculosis and lung disease. – 2012. – Vol. 16, № 12. – P. 1588–1593.Steele M.A., Burk R.F., DesPrez R.M. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest, 1991, vol. 99, no. 2, pp. 465-471.Sasaki T., Svensson E. M., Wang X., Wang Y., Hafkin J., Karlsson M. O., Mallikaarjun S. Population pharmacokinetic and concentration-qtc analysis of delamanid in pediatric participants with multidrug-resistant tuberculosis //Antimicrobial agents and chemotherapy. – 2022. – Vol. 66, № 2. – P. e01608-21.Swaminathan A., Du Cros, P., Seddon J.A., Quinnell S.et al. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications. The International Journal Tuberculosis and Lung Diseases, 2016, vol. 20, no. 4, pp. 474-478.Schaaf H. S. Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach// The Indian Journal of Pediatrics. – 2019. – Vol. 86, № 8. – P. 717–724.Thee S., Garcia-Prats A.J., Donald P.R., Hesseling A.C., Schaaf H.S. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis (Edinb.), 2015, vol. 95, no. 3, pp. 229-4502.Schaaf H. S., Thee S., van der Laan L., Hesseling A. C., Garcia-Prats A. J. Adverse effects of oral second-line antituberculosis drugs in children //Expert opinion on drug safety. – 2016. – Vol. 15, № 10. – P. 1369–1381.Thee S., Zöllner E.W., Willemse M., Hesseling A.C. et al. Abnormal thyroid function tests in children on ethionamide treatment. The International Journal Tuberculosis and Lung Diseases, 2011, vol. 15, no. 9, pp. 1191-1193.Steele M. A., Burk R. F., DesPrez R. M. Toxic hepatitis with isoniazid and rifampin: a meta-analysis // Chest. – 1991. – Vol. 99, № 2. – С. 465–471.Turkova A., Wills G.H., Wobudeya E., Chabala C., Palmer M., Kinikar A., Crook A.M. Shorter treatment for Nonsevere Tuberculosis in African and Indian children. New England Journal of Medicine, 2022, vol. 386, no. 10, pp. 911-922.Swaminathan, A., Du Cros, P., Seddon, J. A., Quinnell, S.et al. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications // The International Journal of Tuberculosis and Lung Disease. – 2016. – Vol. 20, № 4. – P. 474–478.Villarino M.E., Ridzon R., Weismuller P.C., Elcock M., Maxwell R.M., Meador J., Geiter L.J. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. American Journal of Respiratory and Critical Care Medicine, 1997, vol. 155, no. 5, pp. 1735-1738.Thee S., Garcia-Prats A. J., Donald P. R., Hesseling A. C., Schaaf H. S. Fluoroquinolones for the treatment of tuberculosis in children // Tuberculosis (Edinb). – 2015. – Vol. 95, № 3. – P. 229–4502.Wang P.Y., Xie S.Y., Hao Q., Zhang C., Jiang B.F. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. The International Journal Tuberculosis and Lung Diseases, 2012, vol. 16, no. 5, pp. 589-595.Thee S., Zöllner E. W., Willemse M., Hesseling, A. C., et al. Abnormal thyroid function tests in children on ethionamide treatment // The International journal of tuberculosis and lung disease. – 2011. – Т. 15, № 9. – Р. 1191–1193.WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva, World Health Organization, 2022. Available: https://www.who.int/publications/i/item/9789240046764 Accessed August 15, 2023Turkova A., Wills G. H., Wobudeya E., Chabala C., Palmer M., Kinikar A., Crook A. M. Shorter treatment for Nonsevere Tuberculosis in African and Indian children // New England Journal of Medicine. – 2022. – Vol. 386, № 10. – P. 911–922.Zimri K., Casper R., Hoddinott G., Schaaf H.S., Garcia-Prats A.J., Rose P.C., Viljoen, L. A novel approach for eliciting adolescent MDR-TB treatment tolerability: qualitative data from South Africa. The International Journal Tuberculosis and Lung Diseases, 2020, vol. 24, no. 1, pp. 43-47.Villarino M. E., Ridzon R., Weismuller P. C., Elcock M., Maxwell R. M., Meador J., Geiter L. J. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents //American journal of respiratory and critical care medicine. – 1997. – Vol. 155, № 5. – P. 1735–1738.Villarino M. E., Ridzon R., Weismuller P. C., Elcock M., Maxwell R. M., Meador J., Geiter L. J. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents //American journal of respiratory and critical care medicine. – 1997. – Vol. 155, № 5. – P. 1735–1738.Wang P. Y., Xie S. Y., Hao Q., Zhang C., Jiang B. F. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis // The International journal of tuberculosis and lung disease. – 2012. – Vol. 16. – № 5. – P. 589–595.Wang P. Y., Xie S. Y., Hao Q., Zhang C., Jiang B. F. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis // The International journal of tuberculosis and lung disease. – 2012. – Vol. 16. – № 5. – P. 589–595.WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022. URL:https://www.who.int/publications/i/item/9789240046764 [Availablie at 15 Aug 2023]WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022. URL:https://www.who.int/publications/i/item/9789240046764 [Availablie at 15 Aug 2023]Zimri K., Casper R., Hoddinott G., Schaaf H. S., Garcia-Prats A. J., Rose P. C., Viljoen L. A novel approach for eliciting adolescent MDR-TB treatment tolerability: qualitative data from South Africa // The International Journal of Tuberculosis and Lung Disease. – 2020. – Vol. 24, № 1. – P. 43–47.Zimri K., Casper R., Hoddinott G., Schaaf H. S., Garcia-Prats A. J., Rose P. C., Viljoen L. A novel approach for eliciting adolescent MDR-TB treatment tolerability: qualitative data from South Africa // The International Journal of Tuberculosis and Lung Disease. – 2020. – Vol. 24, № 1. – P. 43–47.

The authors declare that there are no conflicts of interest present.